https://www.businesswire.com/news/home/20180723005660/en/

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Jul 23, 2018--Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and non-profit CureDuchenne announced today they have partnered to host a free webinar to provide Duchenne muscular dystrophy patients, caregivers and advocates a comprehensive review of Sarepta’s RNA-targeted technology platforms (PMO and PPMO). Gilmore O’Neill, M.B., M.M.Sc., Chief Medical Officer of Sarepta, will present on behalf of the Company.

The hour-long webinar will take place on Wednesday, July 25, 2018, at 1 p.m. PDT/4 p.m. EDT. Participants must register in advance at :   https://tinyurl.com/y7h8pcex.